PCM
SMMT icon

Prelude Capital Management’s Summit Therapeutics SMMT Stock Holding History

Prelude Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$379K – 1510
2026
Q1 		$379K Buy
+20,000
New +$323K 0.03% 616
2025
Q1 		– Sell
-40,432
Closed -$722K – 1493
2024
Q4 		$722K Buy
+40,432
New +$784K 0.05% 472

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Prelude Capital Management's SMMT Position: Q2 2026 in Review

Prelude Capital Management sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 20,000 shares — an estimated $379K sold.

Prelude Capital Management first reported a position in SMMT in Q4 2024 and held it in 2 quarters. The position peaked at $722K in Q4 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Prelude Capital Management reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 20,000 Summit Therapeutics shares in Q2 2026, an estimated $379K.
  • Prelude Capital Management first reported a position in Summit Therapeutics in Q4 2024 and held it in 2 quarters.
  • Prelude Capital Management's Summit Therapeutics position peaked at $722K in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.